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Abstract
Factors predicting suboptimal CD4 cell recovery have been studied in HIV clade-B infected US and European populations. It
is, however, uncertain to what extent these results are applicable to HIV clade-C infected African populations. Multivariate
analysis using logistic regression and longitudinal analyses using mixed models were employed to assess the impact of age,
gender, baseline CD4 cell count, hemoglobin, body mass index (BMI), tuberculosis and other opportunistic co-infections,
and frequencies of regimen change on CD4 cell recovery at 12 and 30 months and on overtime change in CD4 cells among
442 virologically suppressed South Africans. Despite adequate virological response 37% (95% CI:32%–42%) and 83% (95%
CI:79%–86%) of patients on antiretroviral therapy failed to restore CD4 cell counts $200 cells/mm
3 after 12 and $500 cells/
mm
3 after 30 months, respectively, in this South African cohort. Critical risk factors for inadequate recovery were older age
(p=0.001) and nadir CD4 cell count at ART initiation (p,0.0001), while concurrent TB co-infection, BMI, baseline
hemoglobin, gender and antiretroviral regimen were not significant risk factors. These data suggest that greater efforts are
needed to identify and treat HAART-eligible patients prior to severe CD4 cell decline or achievement of advanced age.
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Introduction
The roll-out of combination antiretroviral therapy has reduced
AIDS-related morbidity and mortality in South Africa [1,2,3,4].
Despite the potency of HAART, it has been observed that a
significant proportion of patients – despite an adequate virological
response – do not achieve CD4 cell recovery above critical
thresholds associated with opportunistic infections. The need to
better understand factors influencing CD4 cell restoration was
underscored by a study from Cape Town, South Africa which
found that CD4 cell count was the variable most strongly
associated with mortality risk during HAART in South Africa
and that a high cumulative mortality risk was associated with
person-time accrued at low CD4 cell counts [2].
Although factors affecting CD4 cell restoration have been
studied in Western cohorts it is uncertain to what extent these
findings are applicable to African populations with HIV-1 clade C
virus and distinct demographic as well as epidemiological
characteristics [5,6,7,8,9,10,11,12]. In this study we retrospectively
examined CD4 cell count trajectories of 442 HIV-1 clade-C
infected Zulu/Xhosa in KwaZulu-Natal Province, South Africa,
who presented with CD4 cell counts ,200 cells/mm
3 at HAART
initiation. Using mixed and logistic regression models we assessed
the predictive value of baseline patient factors, incl. age, gender,
hemoglobin, body-mass-index (BMI), baseline CD4 cell counts,
presence of opportunistic infections (OI) and antiretroviral therapy
regimen on overtime change in CD4 cell counts and CD4 cell
restoration at 12 and 30 months.
Methods
Patients
We included patients $18 years of age with baseline CD4 cell
counts of ,200 cells/ml, who initiated their first HAART regimen
in 2005 and 2006 at McCord Hospital, KwaZulu-Natal Province,
South Africa and who achieved viral suppression, defined as
having had at least 2 consecutive plasma HIV RNA levels ,50
copies/mL within the first 48 weeks of therapy. HAART was
defined as treatment with $3 antiretroviral drugs, including two
nucleoside reverse-transcriptase inhibitors plus a non-nucleoside
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tions after the study baseline were censored when the plasma HIV
RNA level increased above 1000 copies/mL on two occasions, as
this was considered to be treatment failure. Patients were also
censored if they became lost to follow-up, died or if they had no
plasma HIV RNA testing performed for .1 year. Patients who
modified their HAART regimens were not censored when plasma
HIV RNA levels remained ,50 copies/mL. The McCord
Research Ethics Committee, McCord Hospital, Durban, South
Africa and the Partners Human Research Committee, Massachu-
setts General Hospital, Boston, USA both granted ethical approval
for this study. As reviewed by the IRB the clinical data recorded in
this study was considered non-identifiable (research code with no
link), therefore it was determined consent was not required.
Study Measures
Socio-demographic characteristics (including gender and age),
antiretroviral treatment information, CD4 cell counts (at 0, 6, 12,
24 and 30 months post treatment initiation), HIV plasma RNA
levels (at 6, 12, 24 and 30 months post treatment initiation),
hemoglobin (Hgb) level and body-mass-index (BMI) at time of
HAART initiation were collected from computerized clinic
records and patient charts. In addition, clinical information
regarding the presence of Mycobacterium tuberculosis (TB) infection
(pulmonary, extra-pulmonary and TB meningitis) defined by
WHO clinical algorithms, wasting (unintentional loss .10% of
total body weight (TBW)), oral/esophageal candidiasis, chronic
diarrhea, Pneumocystis jirovecii pneumonia, cryotococcal meningitis,
Toxoplasma gondii infection, and Kaposi’s sarcoma were extracted
from patient charts.
Objective
The objective of this analysis was twofold: (1) to identify the
proportion of individuals who experience CD4 cell counts #200
cells/mm
3 and CD4 counts #500 cells/mm
3 after 12 and 30
months of suppressive antiretroviral therapy, respectively, and (2)
to identify factors that are associated with the change in CD4 cell
counts over time in the South African patient population.
Statistical analysis
Confidence intervals for restoration rates were estimated using
methods for exact binomial confidence intervals. Baseline patient
characteristics were compared using Wilcoxon rank sum and
Fisher’s exact tests. Multivariate analysis using logistic regression
was employed to assess the predictors of CD4 cell restoration at
months 12 and 30 ($200 cells/mm
3 after 12 and $500 cells/mm
3
after 30 months). Analysis of repeated measures, using mixed
models, was conducted to assess the overtime change in CD4 cell
counts and identify the predictors of change in CD4 cell counts.
The longitudinal modeling approach utilized in this study allows
the intercept and the rate at which CD4 cell counts change over
time to vary across participants. Moreover, the modeling approach
does not require participants to have the same number of visits or
measurements, and uses all available data instead of eliminating
subjects with missing data, resulting in unbiased estimates of the
model parameters when data are missing at random.
Results
Patient Characteristics
A total of 442 eligible patients who initiated antiretroviral
therapy at McCord Hospital were included in the analyses. Sixty-
one percent were female and the median age was 35.4 years (range
21–69 years) (table 1). Median CD4 cell count at baseline was 94.5
cells/mm
3 (range 1.0–198 cells/mm
3). Median BMI and Hb
values at study entry were 22.7 kg/m
2 (range 13.3–44.2) and
11.2 g/dl (range 4.7–19.6 g/dl), respectively (table 1). The
proportion of patients with pulmonary TB, extra pulmonary TB
and TB meningitis and were 28%, 14% and 1%, respectively.
Overall, 43% of the participants had TB co-infection (pulmonary
TB, TB meningitis or extra pulmonary TB) at study entry (table 1),
Twenty-four percent of the patients presented with chronic
diarrhea, while 31% and 36% had unintentional loss .10% of
total body weight (TBW) and/or oral candidiasis, respectively.
Pneumocystis jirovecii pneumonia, cryotococcal meningitis, Toxoplas-
ma gondii infection and Kaposi’s sarcoma were found in less than
5% of patients at study entry. The majority (81%) of patients
initiated HAART on a combination regimen, including d4T, 3TC
and Efavirenz (table 1). During the 30 months of follow-up, 64%
of patients switched treatment regimens for toxicity at least once,
primarily for neuropathy and lipodystrophy/lipoatrophy, while
16% switched regimens twice or more.
Failure to achieve a normal CD4+ T-cell count after 12
and 30 months of suppressive antiretroviral therapy
Among 442 eligible patients a total of 428 and 427 patients were
available for CD4 analyses at 12 and 30 months respectively. A
total of 163 patients (37%) among the 442 eligible patients, had a
CD4 cell count ,200 cells/mm
3 at 12 month (figure 1A). Among
those individuals, 113 patients eventually had a confirmed increase
in their CD4 cell count to $200 cells/mm
3 after 30 months, but
the remainder 50 subjects had a persistently low CD4 cell count.
Two patients remained below 100 cells/mm
3 throughout the study
follow-up. At 30 months, the majority of patients failed to achieve
CD4 cell counts of $500 cells/mm
3, with only 75 (17%) patients
reaching this threshold (figure 1A).
Predictors of CD4+ cell count restoration at 12 and 30
months
In order to identify the predictors of failure to achieve CD4 cell
restoration $200 cells/mm
3 at month 12 and $500 cells/mm
3 at
month 30, we performed a multivariate analysis, adjusting for
multiple risk factors simultaneously. All variables that were
associated with the outcomes at the 0.4 level in the univariate
analyses were included in a list of candidate variables for the
multivariate analyses. TB co-infection and BMI were included in
the multivariate models regardless of their statistical significance in
the univariate analyses. As shown before in HIV-1 clade B
infection, age at treatment initiation was a strong predictor of CD4
cell restoration in our clade C infected cohort. Patients $40 years
of age were significantly more likely to not achieve CD4 cell counts
.200 cells/mm
3 at 12 month (OR 2.22, 95% CI: 1.37–3.59;
p=0.001) and $500 cells/mm
3 at 30 months (OR 2.83, 95% CI:
1.35–5.92; p=0.0057) (figure 1B). Moreover, baseline CD4 cell
count was another strong predictor of CD4 cell recovery.
Individuals with CD4 cell counts below 50 cells/mm
3 were more
likely to not achieve CD4 cell counts above 200 cells/mm
3
(OR=4.12, 95% CI:2.55–6.64, p,0.0001) and 500 cells/mm
3
(OR=2.06, 95% CI:1.08–3.94, p=0.0294) at 12 and 30 months,
respectively (figure 1B). Other patient characteristics including
gender, baseline BMI or hemoglobin were not associated with
CD4 cell count restoration at 12 or 30 months. Despite a high
prevalence of TB infection at baseline (43%), TB infection at time
of HAART initiation did not undermine CD4 cell recovery. In
contrast, individuals with TB at baseline tended to be at decreased
risk for failure to recover to a CD4 cell counts below 500 cells/
mm
3 at 30 months (OR 0.58, 95% CI: 0.33–1.03; p=0.065)
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infected individuals versus TB negative subjects (median CD4 cell
counts 72 vs 110 cells/mm
3, p=0.0003). Other frequent
symptoms at study entry such as chronic diarrhea, unintentional
weight loss .10% of TBW and oral/esophageal candidiasis were
not associated with increased risk of CD4 cell counts ,200 and
,500 cells/mm
3 at 12 and 30 months, respectively.
CD4 cell count slopes based on pre-therapy
characteristics
There was an overall increase in CD4 cell counts over time,
with an average rate of increase of 8.6660.44 cells/mm
3 per
month (p,0.0001). Although baseline CD4 cell counts were
significantly associated with CD4 cell counts at the subsequent
time points (p,0.0001), the rate of increase in CD4 cell numbers
over time did not vary by baseline CD4 cell counts (p=0.2744).
Baseline age significantly predicted rate of change in CD4 cells
over time (p=0.0002) with lower rates for older (.40 yrs of age)
patients (6.42 cells/mm
3 per month) vs younger (,40 years of age)
patients (8.66 cells/mm
3 per month). Baseline TB co-infection
status was not associated with CD4 cell counts (p=0.5092).
However, TB co-infected individuals showed a trend toward
higher rates of increase in CD4 cells compared to non-TB patients
(9.55 cells/mm
3 versus 8.66 cells/mm
3 per month, p=0.1097).
Gender, BMI status, switch of therapy regimens and treatment
regimen had no effect on the overtime change in CD4 cell counts.
Table 1. CD4 count outcomes at 12 and 30 months based on patient demographic and pre-HAART characteristics.
Variables CD4 counts at 12 months (N=428) CD4 counts at 30 months (N=427)
,200 .200 ,500 .500
Med(min-max) Med(min-max) P-value Med(min-max) P-value
Age 35.4 (20.8–68.9) 37(22–64) 35(21–69) 0.003 36(21–69) 34(22–58) 0.007
Baseline CD4 94.5 (1–198) 55(1–198) 115(1–198) ,0.0001 91(1–198) 109(3–197) 0.05
Hemoglobin 11.2 (4.7–19.6) 11(5–20) 11(6–17) 0.76 11(5–20) 11(5–16) 0.95
,200 .200 ,500 .500
N (%) N (%) N (%) P-value N (%) N (%) P-value
Gender 0.54 0.37
Female 269 (61) 95 (58) 163 (62) 209 (59) 49 (65)
Male 173 (39) 68 (42) 102 (38) 143 (41) 26 (35)
BMI 0.33 0.54
,18.5 52 (13) 21 (14) 29 (12) 42 (13) 9 (12)
18.5–25 225 (54) 90 (58) 129 (53) 188 (56) 33 (50)
$25 135 (33) 44 (29) 87 (36) 103 (31) 25 (38)
TB infection 0.61 0.19
No 245 (57) 93 (58) 145 (56) 200 (58) 36 (49)
Yes 187 (43) 66 (42) 116 (44) 146 (42) 37 (51)
Wasting (.10% loss of TBW) 0.16 0.49
No 297 (69) 102 (64) 185 (71) 235 (68) 53 (73)
Yes 135 (31) 57 (36) 76 (29) 111 (32) 20 (27)
Candidiasis 0.29 0.35
No 277 (64) 96 (60) 172 (66) 224 (65) 43 (59)
Yes 155 (36) 63 (40) 89 (34) 122 (35) 30 (41)
Chronic Diarrhea 0.25 0.46
No 328 (76) 115 (72) 202 (77) 265 (77) 53 (73)
Yes 104 (24) 44 (28) 59 (23) 81 (23) 20 (27)
Treatment at study entry 0.44 0.74
D4T/3TC/EFV 360 (81) 137 (84) 214 (81) 289 (82) 60 (80)
Other 82 (19) 26 (16) 51 (19) 63 (18) 15 (20)
ART switch at 12 month 0.59 -
No 307 (69) 115 (71) 179 (68) - -
Yes 135 (31) 48 (29) 86 (32) - -
ART switch at 30 month - 0.23
No 158 (36) - - 131 (37) 22 (29)
Yes 284 (64) - - 221 (63) 53 (71)
doi:10.1371/journal.pone.0031161.t001
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These data show that despite adequate virological response 37%
and 83% of patients on antiretroviral therapy failed to restore
CD4 cell counts to greater than 200 cells/mm
3 after 12 months
and greater than 500 cells/mm
3 at 30 months, in a South African
cohort under routine program conditions. We also demonstrate
that South African HIV-infected patients initiating antiretroviral
treatment at very depressed CD4 cell counts (,50 cells/mm
3)o r
initiating HAART above the age of 40 years are less likely to
achieve optimal CD4 cell restoration. These results are important
because it has been shown in another South African cohort that
total time spent at a CD4 cell count below 200 cells/mm
3 is linked
to increased morbidity and mortality [2]. These data provide
further evidence that HIV-infected patients, eligible for HAART
in South Africa, should be actively identified earlier in the course
of disease, and at younger age.
Poor CD4 cell restoration is a consistent problem across diverse
HIV-infected cohorts examined to date. The number of
virologically suppressed persons not reaching CD4 cell count
goals at 12 and 30 months in this cohort was comparable to
reports from the United States, and Europe [11,13,14]. Although
the link between low baseline CD4 cell counts ,50cells/mm
3 and
failure to restore CD4 cell count with HAART has been
previously noted, evidence has mainly been derived from
European cohorts [7,9,11,15,16]. The link between age greater
than 40 years and failure to achieve brisk CD4 cell count recovery
has not previously been demonstrated in sub-Saharan Africa
[9,14].
As other studies have defined immunologic non-response, as not
achieving CD4 cell counts $350 after at least a 2-year ART
exposure we expanded our analysis to include the 350 CD4 cell
count cut-off after 30 month of HAART. Age and baseline CD4
cell counts remained strong predictors of failed CD4 cell recovery
(data not shown), while male gender became significantly
associated with failure to restore CD4 cell counts (data not
shown). This data is consistent with prior data linking male gender
to unfavorable CD4 cell count outcome [17].
Interesting, nearly half of our study population presented with
TB co-infection defined by positive AFB smear, radiographical
evidence or high clinical suspicion at ART initiation. Although
HIV/TB co-infected individuals had significantly lower CD4 cell
counts at baseline compared to TB negative individuals, they
showed significantly improved CD4 cell restorations $350 at 30
month (data not shown), with a trend towards more subjects
reaching CD4 cell counts even $500 cells at 30 months. One
possible explanation is that TB co-infection results in additional
CD4 cell count suppression, which resolves with treatment of both
infections [18].
Underlying mechanisms for poor CD4 cell restoration are not
yet clear. However a recent report, among persons with declining
CD4 cell count in the United States despite suppressive HAART,
noted biopsy evidence of lymphoid tissue collagen deposition [19].
It is not known if lymphoid tissue fibrosis is also responsible for
poor CD4 cell reconstitution in South African patients but does
raise important concerns about the reversibility of the underlying
process once underway.
The study had several strengths. We included a relatively large
sample of patients (n=442) observed under routine program
conditions with minimal exclusion criteria. Patients were of Zulu/
Xhosa background and represent a sample that differs significantly
in gender, age, CD4 cell count nadir and co-infection from most
Figure 1. CD4+ T-cell count trajectories and baseline characteristics predicting failure of CD4 cell count recovery. A. CD4+ T-cell count
trajectories for all 442 subjects over the course of 30 months. The red line reflects the median6SEM. B. OR and 95% confidence intervals (CI) for not
achieving CD4 counts above 200 cells/mm
3 at 12 months (grey) and 500 cells/mm
3 at 30 months (black) depending on baseline characteristics.
Shown are only factors with significant or close to significant effect in the multivariate model.
doi:10.1371/journal.pone.0031161.g001
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CD4 cell restoration [7,12,13,14,15,16,20,21,22]. The majority of
our patients were young females, with low CD4 cell nadir (below
100 cells/mm
3) and high prevalence of TB co-infection at
presentation, consistent with the population profile most affected
in Sub-Saharan Africa [23]. Because the majority of our patients
(81%) initiated a regimen containing d4T, 3TC and EFV, we were
able to estimate CD4 cell recovery independent of potential effect
of different ART regimens. During the course of the study, 64% of
patients switched to another regimen, mostly for toxicity reasons
but we found that changing regimen had no impact on CD4 cell
restoration in accord with prior findings [8,15]. Study weaknesses
include the use of CD4 cell count alone as a proxy for immune
restoration, absence of histological evidence to explain potential
mechanisms for failure of CD4 cell recovery and limited
information on clinical consequences of poor CD4 cell count
restoration after the 30 month follow-up such as rates of
opportunistic infections and mortality.
In summary we demonstrate here that a significant proportion
of persons initiating HAART under routine conditions in South
Africa fail to restore CD4 cell count despite adequate virologic
response. Important risk factors are low CD4 cell count nadir and
increased age at HAART initiation consistent with previously
published data from industrialized countries. These data suggest
that greater efforts are needed to identify and treat HAART-
eligible patients prior to severe CD4 cell decline or achievement of
advanced age.
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